Achieving optimal glycemic control, preventing acute events, and minimizing the risk of chronic complications while maintaining a high quality of life are the primary goals of effective diabetes management. However, many insulin-treated people with type 1 diabetes and type 2 diabetes are not achieving the recommended glycemic goals. In addition to the known acute and chronic complications of hyperglycemia, hypoglycemia is a common occurrence that imposes significant health risks. Although rapid-acting and ultra-rapid-acting insulins have demonstrated improved glycemic and safety outcomes over human regular insulin, their delayed onset and extended duration of action, as well as the risk for dosing errors, make hypoglycemia a frequent event for people using these therapies. Technosphere inhaled insulin is a viable option for mealtime insulin coverage and post-meal corrections, providing a “fast on, fast off” insulin activity profile that closely aligns with the timing of glucose absorption from meals to achieve desired postprandial glycemic control while likely minimizing the risk of hypoglycemia. This article discusses the advantages of TI over injected rapid-acting insulin analogs in addressing hypoglycemia fear and the other barriers associated with treatment adherence.
American Diabetes Association. 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes—2025. Diabetes Care, 2025; 48(Supplement_1):S128–S145; doi: 10.2337/dc25-S006
2.
HankoskyER, SchapiroD, GunnKB, et al.Gaps remain for achieving HbA1c targets for people with type 1 or type 2 diabetes using insulin: Results from NHANES 2009–2020. Diabetes Ther, 2023; 14(6):967–975; doi: 10.1007/s13300-023-01399-0
3.
PeyrotM, RubinRR, LauritzenT, et al.Psychosocial problems and barriers to improved diabetes management: Results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med, 2005; 22(10):1379–1385; doi: 10.1111/j.1464-5491.2005.01644.x
4.
YunJS, KoSH. Risk factors and adverse outcomes of severe hypoglycemia in type 2 diabetes mellitus. Diabetes Metab J, 2016; 40(6):423–432; doi: 10.4093/dmj.2016.40.6.423
5.
International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol/L (54 mg/dL) should be reported in clinical trials: A joint position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care, 2017; 40(1):155–157; doi: 10.2337/dc16-2215
6.
PettusJH, ZhouFL, ShepherdL, et al.Incidences of severe hypoglycemia and diabetic ketoacidosis and prevalence of microvascular complications stratified by age and glycemic control in U.S. adult patients with type 1 diabetes: A real-world study. Diabetes Care, 2019; 42(12):2220–2227; doi: 10.2337/dc19-0830
7.
SeaquistER, AndersonJ, ChildsB, et al.Hypoglycemia and diabetes: A report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care, 2013; 36(5):1384–1395; doi: 10.2337/dc12-2480
8.
FrierBM. Hypoglycaemia in diabetes mellitus: Epidemiology and clinical implications. Nat Rev Endocrinol, 2014; 10(12):711–722; doi: 10.1038/nrendo.2014.170
9.
CryerPE. Banting lecture. Hypoglycemia: The limiting factor in the management of IDDM. Diabetes, 1994; 43(11):1378–1389; doi: 10.2337/diab.43.11.1378
10.
WhitmerRA, KarterAJ, YaffeK, et al.Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA, 2009; 301(15):1565–1572; doi: 10.1001/jama.2009.460
11.
FoosV, VarolN, CurtisBH, et al.Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ, 2015; 18(6):420–432.
12.
BrodM, ChristensenT, ThomsenTL, BushnellDM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health, 2011; 14(5):665–671; doi: 10.1016/j.jval.2011.02.001
13.
AmielSA, DixonT, MannR, JamesonK. Hypoglycaemia in Type 2 diabetes. Diabet Med, 2008; 25(3):245–254; doi: 10.1111/j.1464-5491.2007.02341.x
14.
FidlerC, Elmelund ChristensenT, GillardS. Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ, 2011; 14(5):646–655; doi: 10.3111/13696998.2011.610852
15.
ShiL, FonsecaVF, ChildsB. Economic burden of diabetes-related hypoglycemia on patients, payors, and employers. J Diabetes Complications, 2021; 35(6):107916; doi: 10.1016/j.jdiacomp.2021.107916
16.
Gonder-FrederickL, ZrebiecJ, BauchowitzA, et al.Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: A field study. Diabetes Care, 2009; 32(6):1001–1006; doi: 10.2337/dc08-1722
17.
QuilliamBJ, SimeoneJC, OzbayAB, et al.The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care, 2011; 17(10):673–680.
18.
LeeseGP, WangJ, BroomhallJ, et al.; DARTS/MEMO Collaboration. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: A population-based study of health service resource use. Diabetes Care, 2003; 26(4):1176–1180.
19.
WildD, von MaltzahnR, BrohanE, et al.A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns, 2007; 68(1):10–15; doi: 10.1016/j.pec.2007.05.003
20.
WongEY, KroonL. Ultra-rapid-acting insulins: How fast is really needed? Clin Diabetes, 2021; 39(4):415–423; doi: 10.2337/cd20-0119
21.
Popa IlieIR, Vonica-TincuAL, DobreaCM, et al.Safety profiles related to dosing errors of rapid-acting insulin analogs: A comparative analysis using the EudraVigilance database. Biomedicines, 2024; 12(10):2273; doi: 10.3390/biomedicines12102273
22.
RobinsonS, NewsonRS, LiaoB, et al.Missed and mistimed insulin doses in people with diabetes: A systematic literature review. Diabetes Technol Ther, 2021; 23(12):844–856; doi: 10.1089/dia.2021.0164
23.
DatyeKA, BoyleCT, SimmonsJ, et al.; T1D Exchange. Timing of meal insulin and its relation to adherence to therapy in type 1 diabetes. J Diabetes Sci Technol, 2018; 12(2):349–355; doi: 10.1177/1932296817728525
24.
McCarthyM, GreyM. Type 1 diabetes self-management from emerging adulthood through older adulthood. Diabetes Care, 2018; 41(8):1608–1614; doi: 10.2337/dc17-2597.dc17-2597
25.
HirschIB, JunejaR, BealsJM, et al.The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev, 2020; 41(5):733–755.
HeinemannL, BaughmanR, BossA, HompeschM. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol, 2017; 11(1):148–156; doi: 10.1177/1932296816658055
28.
RaskinP, HellerS, HonkaM, et al.Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial. Diabetes Obes Metab, 2012; 14(2):163–173; doi: 10.1111/j.1463-1326.2011.01500.x
RaveK, PotockaE, HeinemannL, et al.Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab, 2009; 11(7):715–720; doi: 10.1111/j.1463-1326.2009.01039.x
34.
HirschIB, BeckRW, MarakMC, et al.; INHALE-3 Study Group. Randomized comparison of postprandial glucose excursion using inhaled insulin versus rapid-acting analog insulin in adults with type 1 diabetes using multiple daily injections of insulin or automated insulin delivery. Diabetes Care, 2024; 47(9):1682–1687; doi: 10.2337/dc24-0838
35.
AkturkHK, Snell-BergeonJK, RewersA, et al.Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: The STAT study. Diabetes Technol Ther, 2018; 20(10):639–647; doi: 10.1089/dia.2018.0200
36.
SeaquistER, BlondeL, McGillJB, et al.Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus. Diabet Med, 2020; 37(5):752–759; doi: 10.1111/dme.14202
37.
HoogwerfBJ, PantaloneKM, BasinaM, et al.Results of 24-week trial of Technosphere insulin versus insulin aspart in type 2 diabetes. Endocr Pract, 2021; 27(1):38–43; doi: 10.1016/j.eprac.2020.11.002
38.
BodeBW, McGillJB, LorberDL, et al.; Affinity 1 Study Group. Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: A randomized 24-week trial. Diabetes Care, 2015; 38(12):2266–2273; doi: 10.2337/dc15-0075
HallerMJ, JonesMC, BhavsarS, KaisermanKB. Time-action profile of technosphere insulin in children with type 1 diabetes. Diabetes Ther, 2023; 14(3):611–617; doi: 10.1007/s13300-023-01368-7
41.
PittasAG, WestcottGP, BalkEM. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol, 2015; 3(11):886–894; doi: 10.1016/S2213-8587(15)00280-6
42.
McGillJB, WeissD, GrantM, et al.Understanding inhaled Technosphere Insulin: Results of an early randomized trial in type 1 diabetes mellitus. J Diabetes, 2021; 13(2):164–172; doi: 10.1111/1753-0407.13099
43.
SebastianSA, CoEL, MehendaleM, HameedM. Insulin analogs in the treatment of type II diabetes and future perspectives. Dis Mon, 2023; 69(3):101417; doi: 10.1016/j.disamonth.2022.101417
44.
SantosVKJD, PradoMLL, Da SilvaGSN, et al.Technosphere insulin in the treatment of Type 1 diabetes mellitus: A systematic review and meta-analysis. J Diabetes Complications, 2025; 39(9):109108; doi: 10.1016/j.jdiacomp.2025.109108
